Is Melatonin Bad for Your Liver or Kidneys?

Melatonin use in the United States has more than quintupled since 1999 — yet questions about its safety for the liver and kidneys persist. The short answer, backed by decades of clinical research: at typical supplemental doses, melatonin has not been shown to harm the liver or kidneys, and emerging evidence suggests it may actually support both organs. But the full picture is more nuanced than that, and a few groups of people should take extra care.

Table of Contents

1. How Your Body Processes Melatonin
2. What the Evidence Shows for the Liver
3. Melatonin and Fatty Liver Disease: A Closer Look
4. What the Evidence Shows for the Kidneys
5. Who Should Be Extra Cautious
6. Why Dose and Formulation Matter
7. The Absorption Advantage: Getting More from Less
8. Frequently Asked Questions
9. Conclusion

1. How Your Body Processes Melatonin

Melatonin is a small, fat-soluble hormone synthesized primarily in the pineal gland from the amino acid tryptophan. After release into the bloodstream, it is metabolized almost entirely in the liver — specifically by cytochrome P450 enzymes — and excreted by the kidneys. This is why both organs are relevant when evaluating supplement safety, and why the question is worth examining properly.

Your body produces melatonin endogenously every night at levels typically between 10 and 80 picograms per milliliter of blood. Supplemental doses of 0.5 mg to 5 mg can raise circulating levels well above this natural range, which is why the liver's metabolic capacity becomes a relevant factor. However, because melatonin is a molecule the liver has evolved to process millions of times over a lifetime, it handles typical supplemental doses without difficulty.

The kidneys' role is primarily excretion: they clear melatonin's metabolites (especially 6-sulfatoxymelatonin) through the urine. People with impaired kidney function may clear melatonin more slowly, which means the hormone stays active in the body longer — an important consideration for dose selection in that group, but not a sign of organ damage from the supplement itself.

2. What the Evidence Shows for the Liver

The most authoritative resource on supplement-related liver injury is the NIH's LiverTox database, which systematically documents every supplement and drug associated with hepatotoxicity. According to the LiverTox entry for melatonin, it has not been implicated in causing serum enzyme elevations or clinically apparent liver injury — and this conclusion holds despite extensive biochemical testing across numerous clinical studies. This is a meaningful finding: a compound used by tens of millions of people, with zero cases of confirmed liver toxicity on record.

The 2016 safety review published in Clinical Drug Investigation, which analyzed human melatonin studies across a range of doses and durations, reached the same conclusion. No studies reported serious adverse events, and adverse effects that did occur — dizziness, headache, nausea — were mild and comparable to placebo. Liver enzyme panels were included in several of these studies, and none returned elevated ALT or AST values attributable to melatonin use.

It is worth noting that a small case report exists linking ramelteon, a prescription melatonin receptor agonist (not melatonin itself), to autoimmune hepatitis. Ramelteon is a synthetic pharmaceutical that acts on the same receptors as melatonin but has a distinct chemical structure and metabolic profile. This case is sometimes cited incorrectly to suggest melatonin causes liver problems — it does not apply to supplemental melatonin.

3. Melatonin and Fatty Liver Disease: A Closer Look

The most surprising finding in the liver safety literature is not that melatonin is neutral — it is that melatonin may actively benefit the liver, particularly in people with non-alcoholic fatty liver disease (NAFLD). NAFLD affects an estimated 24% of the global population and is closely tied to oxidative stress, inflammation, and insulin resistance — three processes melatonin is known to counteract.

A randomized, double-blind, placebo-controlled trial published in the Journal of Research in Medical Sciences in 2020 studied 45 NAFLD patients over 12 weeks. The group receiving 6 mg of melatonin daily showed significant improvements in ALT (p=0.011), AST (p=0.034), hs-CRP levels, and the ultrasound grade of fatty liver compared to placebo. These are standard liver health markers, and their improvement indicates that melatonin was actively reducing liver inflammation rather than causing it.

A separate 100-patient randomized controlled trial found that melatonin significantly decreased liver enzymes and improved fatty liver grade. The review published in the Iranian Journal of Pharmaceutical Research synthesizing clinical evidence on this topic confirmed beneficial effects on NAFLD management and prevention of drug-induced liver toxicity. One human study even found that adding 5 mg of melatonin to standard therapy for drug-induced hepatitis resulted in 81.7% improvement, compared to 66.5% with standard therapy alone. The picture for the liver, in other words, skews positive.

4. What the Evidence Shows for the Kidneys

For the kidneys, the evidence is similarly reassuring — and in some contexts, clearly protective. A 2023 comprehensive review published in the International Journal of Molecular Sciences concluded that melatonin has a renoprotective effect and inhibits the progression of complications connected to renal failure, while noting that exogenous melatonin is well tolerated with low rates of side effects. The review covered acute kidney injury, chronic kidney disease, and drug-induced nephrotoxicity — and across all three contexts, melatonin showed benefit rather than harm.

The most compelling human data comes from a 2025 prospective, randomized, double-blind trial in patients with chronic kidney disease undergoing contrast imaging — a procedure that carries significant risk of contrast-induced acute kidney injury. Melatonin reduced the incidence of acute kidney injury from 60% in the placebo group to 25% in the treatment group — a 58% relative reduction. This was accompanied by significant reductions in cellular oxidative stress at every measured time point.

A systematic review and meta-analysis in Frontiers in Physiology (2022) pooled data from 31 animal studies on renal ischemia-reperfusion injury and found that melatonin significantly reduced blood urea nitrogen by a weighted mean difference of −30.00 (p<0.00001) and serum creatinine by −0.91 (p<0.00001). Both are standard markers of kidney function. These reductions indicate that melatonin preserves kidney function under conditions of acute stress — not the profile of a nephrotoxic compound.

5. Who Should Be Extra Cautious

Despite the overall safety record, certain groups should approach melatonin supplementation more carefully and always consult a healthcare provider before starting. People with existing liver disease — including cirrhosis, autoimmune hepatitis, or active hepatitis — should use particular caution because their liver's metabolic capacity may be reduced, causing melatonin to remain active in the body longer and at higher concentrations than expected.

People with severe chronic kidney disease (CKD stages 4 and 5) or end-stage renal disease on dialysis should also consult a physician, since impaired kidney excretion means melatonin and its metabolites may accumulate. The NIH's NCCIH notes that people taking blood thinners or anticoagulant medications need to be under medical supervision, as melatonin may affect drug metabolism pathways.

People taking medications that are metabolized by CYP1A2 liver enzymes — including some antidepressants, antipsychotics, and blood pressure medications — should also discuss melatonin with their doctor, since melatonin shares some of the same metabolic pathways and may affect drug clearance rates. This is not evidence of liver toxicity; it is a drug-interaction consideration that applies whenever any supplement is taken alongside prescription medications.

• Existing liver disease (cirrhosis, autoimmune hepatitis, active hepatitis B or C): consult hepatologist first
• CKD stages 4–5 or dialysis: renal specialist guidance needed on dose and timing
• CYP1A2-metabolized medications: pharmacist or physician review of interactions
• People with epilepsy: medical supervision recommended per NCCIH guidelines

6. Why Dose and Formulation Matter

One underappreciated aspect of melatonin safety is that dose accuracy with standard supplements is poor. A study published in the Journal of the American Medical Association found that in a review of over-the-counter melatonin gummies, actual melatonin content ranged from 74% to 347% of the labeled dose — and 88% of products were inaccurately labeled. If you think you are taking 5 mg but are actually getting 17 mg, the safety profile changes considerably. Higher doses — particularly above 10 mg/day — are associated with greater rates of minor adverse effects, per the systematic review of 37 RCTs.

The form of melatonin also matters. Standard tablets and gummies must survive the digestive process and first-pass liver metabolism before reaching the bloodstream. Research suggests that standard melatonin formulations achieve only 15–20% bioavailability, meaning a significant portion of what you take is broken down before it reaches circulation. This inefficiency encourages people to take higher doses to compensate — which may explain why commercial products are so often dosed far above what research suggests is necessary.

The NIH's NHANES-based research found melatonin use more than quintupled between 1999 and 2018, with high-dose use (above 5 mg/day) more than tripling during the same period. According to a 2023 narrative review in Frontiers in Neuroscience, melatonin at low to moderate doses (approximately 5–6 mg/day or less) appears safe, and long-term studies comparing it to placebo find no meaningful differences in negative effects. The evidence supports using the lowest effective dose — not the largest available.

7. The Absorption Advantage: Getting More from Less

If dose accuracy and bioavailability are central to melatonin safety, then the formulation you choose is a genuine health decision — not just a marketing consideration. Liposomal melatonin encases the active compound in a phospholipid (fat) shell that mirrors the body's own cell membranes. This allows the melatonin to bypass first-pass liver metabolism and be absorbed directly into the bloodstream, reaching circulation intact rather than being broken down before it can act.

BioAbsorb Nutraceuticals' Liposomal Liquid Melatonin achieves 80–95% bioavailability — compared to 15–20% for standard tablets — and onset begins in 15–30 minutes versus the 60–90 minutes typical of conventional forms. Each full dropper (1 ml) delivers 1.5 mg of melatonin, with a graduated dropper that allows precise dosing down to approximately 0.25 mg increments. At $29.99 for a 100 ml bottle (100 servings), that works out to about $0.30 per dose.

This is not just about convenience. When the dose is accurate and bioavailability is high, you can achieve therapeutic effect with a much smaller amount of melatonin — which is exactly what the research recommends. BioAbsorb's formula is manufactured in a GMP-certified, Health Canada-approved facility, third-party tested on every batch, non-GMO, vegan, and gluten-free. For people concerned about organ health, using a precise, low-dose, high-bioavailability formulation is the logical approach to supplementing responsibly.

Frequently Asked Questions

Can melatonin cause liver damage?

Based on current published evidence, no. The NIH's LiverTox database — the most comprehensive reference for supplement-related liver injury — does not list melatonin as a hepatotoxic compound, and extensive biochemical testing across clinical trials has found no ALT or AST elevations attributable to melatonin. Multiple human studies have included liver enzyme panels as safety endpoints, and none have flagged an issue. If anything, the clinical evidence trends in the opposite direction — toward liver protection at typical supplemental doses.

Is melatonin safe if you have fatty liver disease (NAFLD)?

Multiple clinical trials in NAFLD patients have actually found melatonin beneficial rather than harmful. Melatonin's antioxidant and anti-inflammatory properties address several of the underlying mechanisms driving NAFLD — oxidative stress, elevated liver enzymes, and fat accumulation in hepatocytes. That said, anyone with a diagnosed liver condition should consult their physician before adding any supplement, including melatonin, to their regimen. Monitoring liver enzymes periodically is a reasonable precaution for anyone with pre-existing liver disease.

Can melatonin harm your kidneys?

The published evidence does not support this concern at typical doses. A comprehensive 2023 review found that melatonin has a renoprotective effect and inhibits progression of complications in renal failure. People with advanced chronic kidney disease (stages 4–5) or end-stage renal disease should discuss melatonin with their nephrologist, since impaired excretion could lead to accumulation — but this is about pharmacokinetics, not direct kidney toxicity.

Is it safe to take melatonin every night?

Short-term nightly use (1–3 months) is considered safe for most healthy adults at doses of 5 mg/day or less. Long-term safety data beyond several months is limited — not because problems have been found, but because rigorous long-term trials have not yet been conducted. The NIH recommends consulting a healthcare provider if you plan to use melatonin on an ongoing basis, and the evidence supports using the lowest effective dose rather than high-dose formulations sold in retail stores.

Does stopping melatonin cause withdrawal or rebound effects?

No documented withdrawal syndrome has been associated with melatonin discontinuation, and research has found that exogenous melatonin does not suppress the body's own melatonin production over time. A 2023 review confirmed that withdrawal symptoms have not been reported with cessation of exogenous melatonin. This distinguishes melatonin from other sleep aids — both prescription and OTC — that carry dependence or rebound insomnia risks.

How much melatonin is too much from a safety standpoint?

Research suggests doses above 10 mg/day are associated with a higher rate of minor adverse effects (daytime sleepiness, headache, dizziness), though no life-threatening outcomes have been recorded even at very high doses in clinical settings. The larger practical concern is that melatonin supplement use in the US more than quintupled between 1999 and 2018 while the evidence base for high-dose use remains limited. Most sleep medicine experts recommend starting at 0.5–1 mg and titrating up only as needed — far below what most OTC products contain.

Conclusion

The evidence is clear: at typical supplemental doses, melatonin has not been shown to harm the liver or kidneys — and for people with specific conditions like NAFLD or kidney injury risk, it may offer measurable protective benefits. The most important practical insight is that dose accuracy and bioavailability matter enormously: taking a poorly labeled high-dose tablet is a very different proposition from a low-dose, precisely measured liposomal formulation. If you are choosing a melatonin supplement with your organ health in mind, BioAbsorb's Liposomal Liquid Melatonin gives you precise dosing control, superior absorption, and a clean formulation — so you can use the least melatonin needed to get the result you want.

Research References

1. Melatonin — LiverTox. National Institutes of Health / NCBI Bookshelf (2020). Authoritative NIH review confirming melatonin has not been implicated in causing serum enzyme elevations or clinically apparent liver injury across any published study.
2. The Safety of Melatonin in Humans. Clinical Drug Investigation, Vol. 36 (2016). Review concluding that short-term melatonin is safe even at extreme doses; only mild adverse effects reported; no serious adverse events documented.
3. Adverse Events Associated with Melatonin for the Treatment of Primary or Secondary Sleep Disorders: A Systematic Review. Journal of Pineal Research (2019). Systematic review of 37 randomized controlled trials; no life-threatening or major adverse events identified; most common effects were daytime sleepiness (1.66%), headache (0.74%), and dizziness (0.74%).
4. Benefits and Risks of Melatonin in Hepatic and Pancreatic Disorders: A Review of Clinical Evidences. Iranian Journal of Pharmaceutical Research (2021). Clinical review confirming melatonin's beneficial effects on NAFLD management and prevention of drug-induced liver toxicity; found 81.7% improvement in drug-induced hepatitis with adjunct melatonin therapy.
5. The effect of melatonin on treatment of patients with non-alcoholic fatty liver disease: a randomized double blind clinical trial. Journal of Research in Medical Sciences (2020). 45-patient RCT; 6 mg/day melatonin for 12 weeks significantly improved ALT, AST, hs-CRP, and fatty liver grade versus placebo.
6. Melatonin Treatment in Kidney Diseases. International Journal of Molecular Sciences, Vol. 23 (2023). Comprehensive review concluding that melatonin has renoprotective effects and inhibits progression of renal failure complications; exogenous supplementation well tolerated with low side effects.
7. Protective Effect of Melatonin for Renal Ischemia-Reperfusion Injury: A Systematic Review and Meta-Analysis. Frontiers in Physiology, Vol. 12 (2022). Meta-analysis of 31 animal studies; melatonin significantly reduced blood urea nitrogen (p<0.00001) and serum creatinine (p<0.00001), indicating preservation of kidney function.
8. Protective Effects of Melatonin on Kidney Function Against Contrast Media-Induced Kidney Damage in Patients With Chronic Kidney Disease: A Prospective, Randomized, Double-Blinded, Placebo-Controlled Trial. Journal of Cardiovascular Pharmacology and Therapeutics (2025). 40-patient RCT; melatonin reduced contrast-induced AKI from 60% (placebo) to 25% (treatment group), p=0.025.
9. Chronic Administration of Melatonin: Physiological and Clinical Considerations. Frontiers in Neuroscience (2023). Narrative review concluding that melatonin at ≤5–6 mg/day appears safe; long-term studies find no difference versus placebo in negative effects; no clinically significant adverse effects consistently identified.
10. Melatonin: What You Need To Know. National Center for Complementary and Integrative Health — NIH (2022). Federal health authority overview of melatonin safety, dosage, and considerations; notes short-term use appears safe; long-term data lacking.
11. Trends in Use of Melatonin Supplements Among US Adults, 1999–2018. JAMA, Vol. 327 (2022). NHANES-based study of 55,000+ adults documenting more than fivefold increase in melatonin use and more than tripling of high-dose (>5 mg/day) use over the study period.

About the Author

David Kimbell is a health writer, digital entrepreneur and former aerospace engineer, based in Ottawa, Canada. He loves translating complex science into clear, actionable guidance for consumers seeking evidence-based solutions.

---

Important Disclaimers

Medical Disclaimer: This article provides educational information only and is not intended as medical advice. Always consult with a qualified healthcare provider before starting any new supplement, especially if you have existing health conditions, take medications, or are pregnant or nursing.

FDA/Health Canada Statement: These statements have not been evaluated by the Food and Drug Administration or Health Canada. This product is not intended to diagnose, treat, cure, or prevent any disease.